US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2029
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2029 Report Highlights:
It is anticipated that over 100 clinical studies are being done globally to evaluate investigational transdermal patches, with approximately 50 of them taking place in the US. Neurological illnesses are currently dominating clinical trials in terms of indications. The most prospects are being developed for Parkinson’s and Alzheimer’s diseases. The number of people in the US suffering from neurological diseases has grown in recent years, as contributing environmental variables have increased in this age of modernization. With increased awareness of transdermal patches and their patient-friendliness, they are quickly becoming one of the most popular therapeutic interventions for these disorders. Transdermal patches are attracting interest in the US market for a variety of indications, particularly those that require long term treatment, such as cardiovascular disorders and chronic pain. The US is emerging as a hotspot for transdermal patch development, with many big and small companies executing clinical trials for transdermal patches created for various indications in the region.
Transdermal patches for pain relief are also an important field of study and development in the US. Aside from pain produced by joint difficulties, muscle strains, and nerve damage, among other things, researchers are focusing on pain caused by various health diseases such as cancer or its treatment, as well as pain experienced after specific surgeries. Transdermal patches release the drug at a steady rate over several hours, giving pain relief and serving as the most convenient alternative for pain reduction. Furthermore, unlike oral pain relievers, which can produce unpleasant events such as gastritis, transdermal patches have no substantial side effects.
Several medical universities and health centers in the US are also involved in the research and development of transdermal patches at present, and several of their products are now undergoing late phase clinical trials in the region. For instance, the Washington University School of Medicine is conducting a phase III trial for its buprenorphine transdermal matrix patch in pregnant patients with opioid use disorder. The aim of the trial is to see if the patch can induce opioid withdrawal in these subjects, which will determine the feasibly of the protocol of using patches as a bridge towards using sublingual buprenorphine films. Some others are the University of California, Davis and the Brown University that are conducting trials for oxybutynin and nicotine-based transdermal patches, respectively.
With the rapid approvals of transdermal patches lately, the FDA has also marked itself as an important player in the US market of transdermal patches. The FDA provides a detailed communication on the requirements of an ideal transdermal patch, and patches that meet these are allowed entry in the regional market. In September 2023, the FDA approved Zydus Lifesciences’ transdermal patch to prevent pregnancy. The patch is a generic version of a marketed hormonal patch and contains norelgestromin and ethinyl estradiol as its active ingredients.
The US transdermal patch market offers a plethora of opportunities encouraged by patient convenience, therapeutic versatility and the potential to address healthcare challenges such as pain management and vaccine administration. As technology continues to advance, and as patient preferences shift towards non-invasive and user-friendly drug delivery methods, the market for transdermal patches is expected to experience significant growth. Pharmaceutical companies and researchers are continuously exploring and investing in this field, which will continue in the coming years as well. In addition, as patent protection of some commonly used patches are coming to end, generic competition is expected to drive innovation in the market.
US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2029 Report Highlights:
- US Transdermal Patch Market Opportunity: > US$ 5 Billion By 2029
- Commercially available Patches In US Market: > 25 Patches
- Clinical Insight On All approved transdermal Patches In US Market
- Ongoing Clinical Trials Of Transdermal Patches in US: > 40 Patches
- US Transdermal Patch Clinical Trials Insight By Company, Indication & Phase
- Dosage & Price Insight Of Approved Patches By Indications
- Competitive Landscape
It is anticipated that over 100 clinical studies are being done globally to evaluate investigational transdermal patches, with approximately 50 of them taking place in the US. Neurological illnesses are currently dominating clinical trials in terms of indications. The most prospects are being developed for Parkinson’s and Alzheimer’s diseases. The number of people in the US suffering from neurological diseases has grown in recent years, as contributing environmental variables have increased in this age of modernization. With increased awareness of transdermal patches and their patient-friendliness, they are quickly becoming one of the most popular therapeutic interventions for these disorders. Transdermal patches are attracting interest in the US market for a variety of indications, particularly those that require long term treatment, such as cardiovascular disorders and chronic pain. The US is emerging as a hotspot for transdermal patch development, with many big and small companies executing clinical trials for transdermal patches created for various indications in the region.
Transdermal patches for pain relief are also an important field of study and development in the US. Aside from pain produced by joint difficulties, muscle strains, and nerve damage, among other things, researchers are focusing on pain caused by various health diseases such as cancer or its treatment, as well as pain experienced after specific surgeries. Transdermal patches release the drug at a steady rate over several hours, giving pain relief and serving as the most convenient alternative for pain reduction. Furthermore, unlike oral pain relievers, which can produce unpleasant events such as gastritis, transdermal patches have no substantial side effects.
Several medical universities and health centers in the US are also involved in the research and development of transdermal patches at present, and several of their products are now undergoing late phase clinical trials in the region. For instance, the Washington University School of Medicine is conducting a phase III trial for its buprenorphine transdermal matrix patch in pregnant patients with opioid use disorder. The aim of the trial is to see if the patch can induce opioid withdrawal in these subjects, which will determine the feasibly of the protocol of using patches as a bridge towards using sublingual buprenorphine films. Some others are the University of California, Davis and the Brown University that are conducting trials for oxybutynin and nicotine-based transdermal patches, respectively.
With the rapid approvals of transdermal patches lately, the FDA has also marked itself as an important player in the US market of transdermal patches. The FDA provides a detailed communication on the requirements of an ideal transdermal patch, and patches that meet these are allowed entry in the regional market. In September 2023, the FDA approved Zydus Lifesciences’ transdermal patch to prevent pregnancy. The patch is a generic version of a marketed hormonal patch and contains norelgestromin and ethinyl estradiol as its active ingredients.
The US transdermal patch market offers a plethora of opportunities encouraged by patient convenience, therapeutic versatility and the potential to address healthcare challenges such as pain management and vaccine administration. As technology continues to advance, and as patient preferences shift towards non-invasive and user-friendly drug delivery methods, the market for transdermal patches is expected to experience significant growth. Pharmaceutical companies and researchers are continuously exploring and investing in this field, which will continue in the coming years as well. In addition, as patent protection of some commonly used patches are coming to end, generic competition is expected to drive innovation in the market.
1. RESEARCH METHODOLOGY
2. US TRANSDERMAL PATCH MARKET OUTLOOK
2.1 Approved Transdermal Patches Insight
2.2 Current Market Scenario
2.3 Favorable Market Growth Inhibitors
2.4 Clinical & Commercialization Challenges
2.5 Future Marketing Opportunities
3. BRANDED VS GENERIC TRANSDERMAL PATCHES COMPARISON
4. TRANSDERMAL PATCH CLINICAL & MARKET TRENDS BY INDICATION
4.1 Brain, Neurological & Psychotic Disorders
4.2 Hormone Modulators
4.2.1 Hormone Replacement Therapies (HRT)
4.2.2 Contraception
4.3 Diabetes
4.4 Vaccine
4.5 Substance Use Disorders
4.6 Cardiovascular Diseases
5. US TRANSDERMAL PATCH CLINICAL PIPELINE OVERVIEW
5.1 By Company
5.2 By Drug Class
5.3 By Indication
5.4 By Phase
5.5 By Priority Status
6. CARDIOVASCULAR DISEASES TRANSDERMAL PATCH - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
6.1 Clonidine Transdermal Patch
6.2 Nitroglycerin Transdermal Patch
7. OPIOID DRUG CONTAINING TRANSDERMAL PATCHES - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
7.1 Fentanyl Transdermal Patch
7.2 Buprenorphine Transdermal Patch
8. NEUROLOGICAL DISORDERS TRANSDERMAL PATCH - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
8.1 Selegiline Transdermal Patch
8.2 Rivastigmine Transdermal Patch
8.3 Methylphenidate Transdermal Patch
8.4 Asenapine Transdermal Patch
8.5 Rotigotine Transdermal Patch (Neupro) sales
8.6 Donepezil Transdermal Patch
8.7 Dextroamphetamine Transdermal Patch
9. HORMONAL THERAPY TRANSDERMAL PATCH - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
9.1 Estradiol Transdermal Patch
9.2 Testosterone Transdermal Patch (Androderm)
10. TRANSDERMAL PATCHES FOR OTHER CONDITIONS - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
10.1 Nicotine Transdermal Patch
10.2 Oxybutynin Transdermal Patch
10.3 Granisetron Transdermal Patch (Sancuso)
11. US TRANSDERMAL PATCH CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE
11.1 Research
11.2 Preclinical
11.3 Phase-I
11.4 Phase-II
11.5 Phase-III
11.6 Preregistration
11.7 Registered
12. US COMMERCIALLY AVAILABLE TRANSDERMAL PATCHES CLINICAL INSIGHT BY INDICATION
13. COMPETITIVE LANDSCAPE
13.1 AbbVie
13.2 AFYX Therapeutics
13.3 Agile Therapeutics
13.4 Bayer HealthCare Pharmaceuticals
13.5 Corsair Pharma
13.6 DBV Technologies
13.7 Hisamitsu Pharmaceutical
13.8 IBSA
13.9 Privo Technologies
13.10 Psilera
13.11 Starton Therapeutics
13.12 Teikoku Pharma USA
13.13 Teikoku Seiyaku
13.14 UCB
13.15 Vaxess Technologiess
13.16 Verndari
2. US TRANSDERMAL PATCH MARKET OUTLOOK
2.1 Approved Transdermal Patches Insight
2.2 Current Market Scenario
2.3 Favorable Market Growth Inhibitors
2.4 Clinical & Commercialization Challenges
2.5 Future Marketing Opportunities
3. BRANDED VS GENERIC TRANSDERMAL PATCHES COMPARISON
4. TRANSDERMAL PATCH CLINICAL & MARKET TRENDS BY INDICATION
4.1 Brain, Neurological & Psychotic Disorders
4.2 Hormone Modulators
4.2.1 Hormone Replacement Therapies (HRT)
4.2.2 Contraception
4.3 Diabetes
4.4 Vaccine
4.5 Substance Use Disorders
4.6 Cardiovascular Diseases
5. US TRANSDERMAL PATCH CLINICAL PIPELINE OVERVIEW
5.1 By Company
5.2 By Drug Class
5.3 By Indication
5.4 By Phase
5.5 By Priority Status
6. CARDIOVASCULAR DISEASES TRANSDERMAL PATCH - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
6.1 Clonidine Transdermal Patch
6.2 Nitroglycerin Transdermal Patch
7. OPIOID DRUG CONTAINING TRANSDERMAL PATCHES - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
7.1 Fentanyl Transdermal Patch
7.2 Buprenorphine Transdermal Patch
8. NEUROLOGICAL DISORDERS TRANSDERMAL PATCH - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
8.1 Selegiline Transdermal Patch
8.2 Rivastigmine Transdermal Patch
8.3 Methylphenidate Transdermal Patch
8.4 Asenapine Transdermal Patch
8.5 Rotigotine Transdermal Patch (Neupro) sales
8.6 Donepezil Transdermal Patch
8.7 Dextroamphetamine Transdermal Patch
9. HORMONAL THERAPY TRANSDERMAL PATCH - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
9.1 Estradiol Transdermal Patch
9.2 Testosterone Transdermal Patch (Androderm)
10. TRANSDERMAL PATCHES FOR OTHER CONDITIONS - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS
10.1 Nicotine Transdermal Patch
10.2 Oxybutynin Transdermal Patch
10.3 Granisetron Transdermal Patch (Sancuso)
11. US TRANSDERMAL PATCH CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE
11.1 Research
11.2 Preclinical
11.3 Phase-I
11.4 Phase-II
11.5 Phase-III
11.6 Preregistration
11.7 Registered
12. US COMMERCIALLY AVAILABLE TRANSDERMAL PATCHES CLINICAL INSIGHT BY INDICATION
13. COMPETITIVE LANDSCAPE
13.1 AbbVie
13.2 AFYX Therapeutics
13.3 Agile Therapeutics
13.4 Bayer HealthCare Pharmaceuticals
13.5 Corsair Pharma
13.6 DBV Technologies
13.7 Hisamitsu Pharmaceutical
13.8 IBSA
13.9 Privo Technologies
13.10 Psilera
13.11 Starton Therapeutics
13.12 Teikoku Pharma USA
13.13 Teikoku Seiyaku
13.14 UCB
13.15 Vaxess Technologiess
13.16 Verndari
LIST OF TABLES
Table 2-1: US – Currently Available Branded Transdermal Patches
Table 2-2: Features Required in Transdermal Patches
Table 3-1: Comparison of Features of Branded & Generic Patches
Table 7-1: Butrans – Initial Dose Calculation using Previous Opioid (Morphine) Dosage
Table 8-1: Daytrana - Recommended Titration Schedule for ADHD Treatment
Table 2-1: US – Currently Available Branded Transdermal Patches
Table 2-2: Features Required in Transdermal Patches
Table 3-1: Comparison of Features of Branded & Generic Patches
Table 7-1: Butrans – Initial Dose Calculation using Previous Opioid (Morphine) Dosage
Table 8-1: Daytrana - Recommended Titration Schedule for ADHD Treatment
